PE20020322A1 - Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2 - Google Patents
Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2Info
- Publication number
- PE20020322A1 PE20020322A1 PE2001000821A PE2001000821A PE20020322A1 PE 20020322 A1 PE20020322 A1 PE 20020322A1 PE 2001000821 A PE2001000821 A PE 2001000821A PE 2001000821 A PE2001000821 A PE 2001000821A PE 20020322 A1 PE20020322 A1 PE 20020322A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- agent
- cyclooxygenase
- methylsulfonil
- phenyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 2
- 238000004090 dissolution Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- 229930195725 Mannitol Natural products 0.000 abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 239000000594 mannitol Substances 0.000 abstract 2
- 235000010355 mannitol Nutrition 0.000 abstract 2
- -1 3-HYDROXY-3-METHYL-1-BUTOXY Chemical class 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229960000590 celecoxib Drugs 0.000 abstract 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 abstract 1
- 229960003314 deracoxib Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229960004945 etoricoxib Drugs 0.000 abstract 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 239000007935 oral tablet Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229960000371 rofecoxib Drugs 0.000 abstract 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 229960002004 valdecoxib Drugs 0.000 abstract 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE UNA COMPOSICION ORAL DE RAPIDA DISOLUCION QUE COMPRENDE a)IMPEDIR LA AGLOMERACION AGREGANDO DE 0,05% A 5% DE UN HUMECTANTE (LAURIL SULFATO DE SODIO) PREVIAMENTE A LA DROGA b)GRANULAR EN HUMEDO i)DE 1% A 75% DE UN INHIBIDOR DE CICLOOXIGENASA 2 DE FORMULA I DONDE R3 ES METILO, AMINO; R4 ES H, ALQUIL, ALCOXI C1-C4; X ES N, CR5; R5 ES H, HALOGENO; Y E Z SON C, N; SIENDO COMPUESTOS PREFERIDOS CELECOXIB, DERACOXIB, VALDECOXIB, ROFECOXIB, ETORICOXIB, 2-(3,5-DIFLUOROFENIL)-3-[4-METILSULFONIL)FENIL]-2-CICLOPENTEN-1-ONA, ACIDO (S)-6,8-DICLORO-2-(TRIFLUOROMETIL)-2H-1-BENZOPIRAN-3-CARBOXILICO; 2-[3,4-DIFLUOROFENIL)-4-(3-HIDROXI-3-METIL-1-BUTOXI)-5-[4-(METILSULFONIL)FENIL]-3-(2H)-PIRIDAZINONA; JUNTO CON ii)UN AGENTE AGLUTINANTE QUE COMPRENDE DE 1% A 10% DE UN SACARIDO DE ALTA MOLDEABILIDAD COMO LACTOSA, MANITOL, GLUCOSA, ENTRE OTROS; O DE 10% A 90% DE UN SACARIDO DE BAJA MOLDEABILIDAD COMO MANITOL DE GRADO EN POLVO SIENDO LA PROPORCION DE 2:100 A 20:100; c)MEZCLAR LOS GRANULOS CON UN LUBRICANTE, UN AGENTE EDULCORANTE, UN AGENTE SABORIZANTE PARA FORMAR UNA MEZCLA EN FORMA DE TABLETA; d)COMPRIMIR LA MEZCLA PARA FORMAR TABLETAS ORALES DE RAPIDA DISOLUCION; e)AGREGAR DE 0,05% A 5% DE UN DESLIZANTE COMO DIOXIDO DE SILICIO; TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE EL INHIBIDOR DISPERSADO EN UNA MATRIZ QUE COMPRENDE UN SACARIDO DE BAJA Y ALTA MALDEABILIDAD QUE SE DESINTEGRA EN UNOS 30 A 300 SEGUNDOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22634900P | 2000-08-18 | 2000-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020322A1 true PE20020322A1 (es) | 2002-05-10 |
Family
ID=37515865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000821A PE20020322A1 (es) | 2000-08-18 | 2001-08-17 | Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20020119193A1 (es) |
| AR (1) | AR030382A1 (es) |
| PE (1) | PE20020322A1 (es) |
| TW (1) | TWI256305B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| WO2004026235A2 (en) * | 2002-09-20 | 2004-04-01 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| US20050025791A1 (en) * | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| CA2477923C (en) | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| RS20050390A (sr) * | 2002-11-26 | 2008-04-04 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg., | Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor |
| GB0228465D0 (en) * | 2002-12-06 | 2003-01-08 | Univ Belfast | A method of treating disease |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| AT413944B (de) * | 2003-05-27 | 2006-07-15 | Binder Eva Dkfm | Verwendung von oxicam-verbindungen |
| BRPI0415753A (pt) * | 2003-10-21 | 2006-12-19 | Pharmacia Corp | método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm |
| US20050113410A1 (en) * | 2003-11-03 | 2005-05-26 | Mark Tawa | Pharmaceutical salts of zafirlukast |
| CA2563575C (en) * | 2004-04-29 | 2012-12-18 | Binder, Eva | Enantiomerically pure hexahydropyrrolocyclopentapyridine derivatives |
| MXPA06015027A (es) * | 2004-06-30 | 2007-02-08 | Albemarle Corp | Granulos de alto contenido de ibuprofeno y su preparacion y su uso en formas de dosificacion farmaceutica. |
| CA2626234A1 (en) * | 2005-12-22 | 2007-06-28 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| US20070148245A1 (en) * | 2005-12-22 | 2007-06-28 | Ilan Zalit | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| EP1808163A1 (en) * | 2005-12-22 | 2007-07-18 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| EP2064252A2 (en) * | 2006-09-01 | 2009-06-03 | Usv Limited | Process for the preparation of sevelamer hydrochloride and formulation thereof |
| HUE035406T2 (en) * | 2007-10-08 | 2018-05-02 | Intrexon Corp | Engineered dendritic cells and uses for the treatment of cancer |
| AU2010209293A1 (en) * | 2009-01-22 | 2011-09-08 | Usv Limited | Pharmaceutical compositions comprising phosphate-binding polymer |
| CN104027319A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 一种塞来昔布分散片及其制备方法 |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| CN108057025A (zh) * | 2017-12-08 | 2018-05-22 | 佛山市弘泰药物研发有限公司 | 一种依托考昔口崩片及其制备方法 |
| CN111407733A (zh) * | 2020-03-19 | 2020-07-14 | 大桐制药（中国）有限责任公司 | 一种塞莱昔布片剂的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1178795A1 (en) * | 1999-05-17 | 2002-02-13 | Ilex Oncology, Inc. | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| ES2299441T3 (es) * | 1999-12-08 | 2008-06-01 | Pharmacia Corporation | Forma en estado solido de celecoxib con biodisponibilidad potenciada. |
-
2001
- 2001-08-17 PE PE2001000821A patent/PE20020322A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103961A patent/AR030382A1/es unknown
- 2001-08-17 US US09/932,494 patent/US20020119193A1/en not_active Abandoned
- 2001-08-17 TW TW090120287A patent/TWI256305B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AR030382A1 (es) | 2003-08-20 |
| TWI256305B (en) | 2006-06-11 |
| US20020119193A1 (en) | 2002-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020322A1 (es) | Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2 | |
| ES2307041T3 (es) | Tableta que contiene ester etilico del acido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico o sus sales. | |
| RU2436780C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| RU2319701C2 (ru) | ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I | |
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| UA84318C2 (ru) | Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе | |
| KR960041166A (ko) | 4-(아릴아미노 메틸렌)-2,4-디하이드로-3-피라졸론 | |
| PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
| CA2634676A1 (en) | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp | |
| MY189572A (en) | Hiv replication inhibiting pyrimidines | |
| PE20020799A1 (es) | Una composicion farmaceutica con tendencia reducida a la cristalizacion del farmaco | |
| TNSN07145A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| TR200001530T2 (tr) | Gastrik asit salgılamasının önlenmesi için heterosiklik bileşimler | |
| HRP20100283T1 (hr) | Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor | |
| AR066780A1 (es) | Formulaciones que contienen triazinonas y hierro | |
| YU2803A (sh) | 4-fenil-piridin derivati kao antagonisti neurokinin-1 receptora | |
| CA2624621A1 (en) | Pyrazine derivatives | |
| SE9903831D0 (sv) | Formulation of substituted benzimidazoles | |
| PE20040084A1 (es) | Combinaciones de medicamentos que contienen compuestos heterociclicos y un nuevo agente anticolinergico | |
| NO304227B1 (no) | Substituerte imidazolderivater, preparat som inneholder disse og deres anvendelse | |
| SE0201194D0 (sv) | New compounds | |
| PE20010254A1 (es) | Pesticidas a base de derivados de indazol o benzotriazol | |
| CY1111578T1 (el) | Σουλφαμιδες ως antαγωνιστες του υποδοχεα ενδοθηλινης για τη θεραπεια καρδιαγγειακων νοσων | |
| MY151470A (en) | Controlled release solid preparation | |
| PE20061155A1 (es) | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |